We are pleased to invite you to the webinar titled ‘Updated EULAR recommendations in RA1 & PsA2’. The objective of this online meeting is to share with the International Rheumatology Community the 2020 updated EULAR recommendations for the management of RA and PsA, with a focus on JAKi and IL- 17i respectively. Two clinical cases that speak to the cited recommendations will be discussed.
1Olumiant is indicated for the treatment of moderate-to-severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs.
2Taltz, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies.
INT-LR-BE-0072; PP-AU-DE-0251; PP-LR-CZ-0049; PP-BA-KR-0188; PP-IX-KR-0263; PP-AU-AT-0114; PP-BA-PL-0133; PP-AU-HU-0142; PP-BA-RO-0439; PP-BA-PT-0121/MAR2020
This webinar has been developed, organised and funded by Eli Lilly and Company Ltd. Intended for Healthcare Professionals only. Lilly products will be discussed at this meeting.
? This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Adverse events and product complaints should be reported. Reporting forms and further information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store, or Ireland: www.hpra.ie. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000, or Lilly Ireland on 01 664 0446.